SCHEMBL19785519

SCHEMBL19785519

CCCCC(CC)COC(=O)CCSc1ccnc(F)c1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 3/20 0.48
▸ TSHR P16473 3/20 0.48
▸ TDP1 Q9NUW8 2/20 0.48
▸ ATM Q13315 1/20 0.48
▸ ALDH1A1 P00352 6/20 0.45
▸ MAPK1 P28482 3/20 0.45
▸ CA2 P00918 1/20 0.41
▸ LMNA P02545 5/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ RECQL P46063 1/20 0.38
▸ PRSS1 P07477 1/20 0.38
▸ PRSS2 P07478 1/20 0.38
▸ PRSS3 P35030 1/20 0.38
▸ THRB P10828 2/20 0.34
▸ PDE1A P54750 1/20 0.31
▸ PDE1B Q01064 1/20 0.31
▸ PDE1C Q14123 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ GAA P10253 1/20 0.30
▸ PKM P14618 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19785248 0.90 CYP3A4 (0.50) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL22980314 0.89 CYP3A4 (0.39) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL21383708 0.89 CYP3A4 (0.49) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL31057983 0.89 CYP3A4 (0.49) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL19785269 0.88 CYP3A4 (0.48) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL29679787 0.88 CYP3A4 (0.48) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL21383626 0.88 CYP3A4 (0.48) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL21856067 0.87 CYP3A4 (0.47) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL21154729 0.87 CYP3A4 (0.46) CYP3A4TSHRTDP1ATMALDH1A1
SCHEMBL21154771 0.86 TSHR (0.46) CYP3A4TSHRTDP1ATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116478131-A 2, 5-disubstituted and 2,5, 6-trisubstituted 3-methylpyrazines as allosteric SHP2 inhibitors 锐新医药公司 2023-07-25 — — CN disclosed
CN-116478132-A 2, 5-disubstituted and 2,5, 6-trisubstituted 3-methylpyrazines as allosteric SHP2 inhibitors 锐新医药公司 2023-07-25 — — CN disclosed
US-11661401-B2 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors Revolution Medicines, Inc. (US) 2023-05-30 — — US disclosed
US-11661401-B2 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors Revolution Medicines, Inc. (US) 2023-05-30 — — US disclosed
CN-109983001-B 2, 5-disubstituted 3-methylpyrazines and 2,5, 6-trisubstituted 3-methylpyrazines as allosteric SHP2 inhibitors 锐新医药公司 2023-04-04 — — CN disclosed
CN-114728935-A SHP2 inhibitor IRBM股份公司 2022-07-08 — — CN disclosed
US-20210101870-A1 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2021-04-08 — — US disclosed
US-20190210977-A1 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2019-07-11 — — US disclosed
WO-2018013597-A1 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS Revolution Medicines, Inc. (US) 2018-01-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11661401-B2 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors PTPN5, PTPN22, PTPN2 CYP3A4 4174/4885TSHR 1870/4885TDP1 2479/4885
US-20190210977-A1 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS PTPN5, PTPN2, PTPN22 CYP3A4 4433/4885TSHR 1650/4885TDP1 2244/4885
US-20210101870-A1 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS PTPN5, PTPN22, PTPN2 CYP3A4 4174/4885TSHR 1870/4885TDP1 2479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback